Volume 1 - Issue 1, November-December 2007 - Exhibitors @ RSNA 2010

First Patient Enrolled in Clinical Trial to Study Drug Sluting Stent Treatment in Women

Abbott has announced that the first patient was enrolled in its Xience V Spirit Women clinical trial, the world’s first clinical trial designed to study the safety and effectiveness of drug eluting stent treatment in women. Liliana Grinfeld, M.D., of the Hospital Italiano in Buenos Aires, Argentina, performed the first procedure.
The goal of the trial is to increase understanding of how heart disease affects women and to assess the performance of the Xience™ V Everolimus Eluting Coronary Stent System in women with previously untreated coronary artery lesions from Europe, Asia-Pacific, Canada and Latin America. The trial will focus on specific aspects of women’s health in relation to coronary artery disease such as general awareness about the disease, symptoms at time of presentation, referral patterns, and hormonal menopausal status.

Print as PDF
Abbott has announced that the first patient was enrolled in its Xience V Spirit Women clinical trial, the world’s first clinical trial designed to study th

No comment


Please login to leave a comment...